Taking stock of the evidence for ‘off-label’ use of cancer drugs

Doctors often expand the use of cancer drugs to situations beyond those explicitly approved by the Food and Drug Administration. And health plans will pay for those uses as long as they are supported...

Charting the financial conflicts of doctors on Twitter

A detailed look at the tweeting habits of more than 600 hematologist-oncologists found that 72 percent were recipients of industry money for consulting, travel, lodging, or food and beverage. It's...

Sizing up the FDA’s revolving door with industry

When reviewers with the Food and Drug Administration weigh the evidence for a drug company's experimental treatment, how many are thinking: I may someday work for that company? It's a difficult...